PMS-NIFEDIPINE ER TABLET (EXTENDED-RELEASE)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
05-01-2017
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
NIFEDIPINE
Tillgänglig från:
PHARMASCIENCE INC
ATC-kod:
C08CA05
INN (International namn):
NIFEDIPINE
Dos:
30MG
Läkemedelsform:
TABLET (EXTENDED-RELEASE)
Sammansättning:
NIFEDIPINE 30MG
Administreringssätt:
ORAL
Enheter i paketet:
30/100
Receptbelagda typ:
Prescription
Terapiområde:
DIHYDROPYRIDINES
Produktsammanfattning:
Active ingredient group (AIG) number: 0115253004; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2014-01-08
Produktens egenskaper
PRODUCT MONOGRAPH
PR
PMS-NIFEDIPINE ER
Nifedipine Extended-Release Tablets, House Standard
20 mg, 30 mg and 60 mg Nifedipine
Antianginal/Antihypertensive Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
Date of Revision:
December 14, 2016
Submission Control No: 200335
_ _
_pms-NIFEDIPINE ER Product Monograph _
_Page 2 of 43_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II: SCIENTIFIC INFORMATION
...............................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
........................................................................................................
Läs hela dokumentet
